Evidence Hub

LB1053 Dysregulation of antioxidant enzyme PRDX5 in alopecia areata

A. Abdelaziz, M. Mian, S. Erjavec, S. Gelfman, P. Lin, I. Ionita-Laza, L. Petukhova, A. Christiano

Journal of Investigative Dermatology, 2019

1 citation

Abstract

LB1052 Characterization of the B cell infiltrate in discoid lupus 1 2 3 4 5 4,5 MB Rapp , N Babkowski , F Esaa , T Curran , JH Anolik and CT Richardson 1 University of Buffalo, Buffalo, New York, United States, 2 University of Rochester, Rochester, New York, United States, 3 School of Medicine and Dentistry, University of Rochester, Rochester, New York, United States, 4 Dermatology, University of Rochester, Rochester, New York, United States and 5 Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, New York, United States Discoid lupus erythematosus (DLE) is a severely disfiguring and difficult to treat autoimmune skin disease for which no new therapies have been FDA-approved in over 60 years. One potential therapeutic target is cutaneous B cells. Though rare in healthy skin, B cells are prevalent in DLE lesions, comprising 10-20% of the robust lymphocytic infiltrate. However, the phenotype and function of this expanded B cell population have not been evaluated in detail and it is unknown whether cutaneous B cells play a role in DLE pathogenesis. We analyzed T cells (CD3), B cells (CD20), and plasma cells (CD138) by immunohistochemistry in skin biopsies from seventeen patients with a clinical and pathologic diagnosis of discoid lupus. Consistent with known literature, T cells predominated the infiltrate (180.3 cells/hpf, range 88-299). However, the number of B cells was not insignificant and comprised an average of 21% of the total lymphocytic…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free